N¹-((4-(1H-pyrazol-4-yl)phenyl)(4-chlorophenyl)methyl)ethane-1,2-diamine | 917900-46-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N¹-((4-(1H-pyrazol-4-yl)phenyl)(4-chlorophenyl)methyl)ethane-1,2-diamine
• 英文别名: N*1*-{(4-Chloro-phenyl)-[4-(1H-pyrazol-4-yl)-phenyl]-methyl}-ethane-1,2-diamine；N'-[(4-chlorophenyl)-[4-(1H-pyrazol-4-yl)phenyl]methyl]ethane-1,2-diamine
• CAS: 917900-46-0
• 化学式: C₁₈H₁₉ClN₄
• 分子量: 326.829
• InChiKey: WYQNADNUGPFGRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  66.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-((4-溴苯基)-(4-氯苯基))甲醇 在 四(三苯基膦)钯 、 氯化亚砜 、 碳酸氢钠 、 potassium carbonate 、 potassium iodide 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 12.33h， 生成 N¹-((4-(1H-pyrazol-4-yl)phenyl)(4-chlorophenyl)methyl)ethane-1,2-diamine
  参考文献：
  名称：

  Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors

  摘要：

  A series of diphenylmethylamine derivatives were rationally designed, synthesized and biologically evaluated. Most of them exhibited moderate to good Aktl inhibitory activities, as well as promising antiproliferative efficacy against cancer cell lines. Besides, molecular docking studies were carried out to probe their binding modes with Aktl. Further kinase selectivity studies of compound 22c were performed, indicating its excellent selectivity against Aurora A, Drak, IKK beta, GSK3 beta, SYK and JAK2, and moderate selectivity against PKC and BRAF. Finally, a refined pharmacophore model was generated using the most active compounds 2, 12c and 22c via application of HipHop program. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.11.036

文献信息

• Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors
  申请人：Woodhead Steven John

  公开号：US20100210617A1

  公开（公告）日：2010-08-19

  The invention provides a compound of the formula (II): or a salt, solvate, tautomer or N-oxide thereof; wherein n is 0 or 1; one of Y 1 and Y 2 is CH and the other is selected from CH, CR 8 and N; q is 0, 1 or 2 provided that q is 0 or 1 when Y 1 or Y 2 is CR 8 ; R 1 aryl or heteroaryl group of 5 to 10 ring members; R 2a and R 3a each are hydrogen, C 1-4 hydrocarbyl or C 1-4 acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by fluorine, hydroxy, amino, methylamino, dimethylamino or methoxy; or NR 2a R 3a forms an imidazole group or a saturated monocyclic 4-7 membered heterocyclic group optionally containing a second heteroatom ring member selected from O and N; R 18 is hydrogen or methyl; R 19 is hydrogen or methyl; R 24 is hydrogen or R 24 , R 2a and the intervening nitrogen atom and carbon atoms together form an azetidine, pyrrolidine or piperidine ring; R 25 is hydrogen or a C 1-4 alkyl group wherein the C 1-4 alkyl group is optionally substituted by hydroxy or amino provided that there are at least two carbon atoms between the hydroxy or amino group and the oxygen atom to which R 25 is attached; and R4 and R 5 each are hydrogen or a substituent as defined in the claims

  本发明提供了化合物的公式(II)或其盐、溶剂化物、互变异构体或N-氧化物；其中n为0或1；Y1和Y2中的一个是CH，另一个选自CH、CR8和N；q为0、1或2，但当Y1或Y2为CR8时，q为0或1；R1为5到10个环成员的芳基或杂环基团；R2a和R3a各自为氢、C1-4烃基或C1-4酰基，其中烃基和酰基基团可选地被氟、羟基、氨基、甲基氨基、二甲基氨基或甲氧基取代；或NR2aR3a形成咪唑环或饱和的单环4-7成员杂环基团，可选地包含第二个杂原子环成员，所选自O和N；R18为氢或甲基；R19为氢或甲基；R24为氢或R24、R2a和介于其间的氮原子和碳原子共同形成氮杂环，所选自氮杂环、吡咯烷或哌啶环；R25为氢或C1-4烷基基团，其中C1-4烷基基团可选地被羟基或氨基取代，但在R25连接的氧原子和羟基或氨基基团之间至少有两个碳原子；而R4和R5各自为氢或如权利要求中所定义的取代基。